@article{ref1,
title="An early clinical phase II study of SME3110 (fluvoxamine maleate), a selective serotonin reuptake inhibitor, in the treatment of depression and depressive state",
journal="Japanese Journal of Neuropsychopharmacology",
year="1996",
author="Murasaki, M. and Kamijima, K. and Yamauchi, T. and Miura, S. and Kariya, T. and Mori, A. and Hasegawa, K. and Toru, M. and Hirose, T. and Yamaguchi, N. and Asai, M. and Yamashita, I. and Endo, S. and Kitanishi, K. and Nomura, S.",
volume="18",
number="3",
pages="191-204",
abstract="SME3110 was given to 74 patients with depression or depressive state in order to investigate it's efficacy and safety. SME3110 was administrated in the doses ranging from an initial dose of 50 mg/day to a maximum dose of 300 mg/day for 6 weeks, following a fixed flexible dosing design. As shown in changes of the scores on the Hamilton Depression Rating Scale and the CPRG Rating Scale, SME3110 excellently improved psychiatric symptoms including 'depressed mood,' 'suicide,' and 'psychic anxiety' and a suppressed volition or mood. Further, the drug had an effect on sleep disorder or physical symptoms such as 'decreased appetite.' The efficacy assessment revealed the improvement rate of 55.6% (40 of 72 patients). In the safety assessment, SME3110 was demonstrated to be highly safe, with the rate of 62.2% (46 of 74 patients) in patients with no safety problem. The most common adverse reaction was nausea. SME3110 produced a lower incidence of anticholinergic adverse reactions including dry mouth, constipation, and dizziness/vertigo. The usefulness assessment showed the usefulness rate of 52.7% (39 of 74 patients). Thus, SME3110 is concluded to exert excellent antidepressive effect and to be highly safe, with a lower incidence of anticholinergic adverse reactions.<p /><p>Language: ja</p>",
language="ja",
issn="0388-7588",
doi="",
url="http://dx.doi.org/"
}